NTRA vs. EXAS, DGX, LH, RDNT, FTRE, UHS, SOLV, THC, UTHR, and INCY
Should you be buying Natera stock or one of its competitors? The main competitors of Natera include Exact Sciences (EXAS), Quest Diagnostics (DGX), Laboratory Co. of America (LH), RadNet (RDNT), Fortrea (FTRE), Universal Health Services (UHS), Solventum (SOLV), Tenet Healthcare (THC), United Therapeutics (UTHR), and Incyte (INCY). These companies are all part of the "medical" sector.
Natera (NASDAQ:NTRA) and Exact Sciences (NASDAQ:EXAS) are both large-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, earnings, institutional ownership, valuation, community ranking, dividends, profitability and media sentiment.
Exact Sciences has higher revenue and earnings than Natera. Exact Sciences is trading at a lower price-to-earnings ratio than Natera, indicating that it is currently the more affordable of the two stocks.
In the previous week, Exact Sciences had 1 more articles in the media than Natera. MarketBeat recorded 18 mentions for Exact Sciences and 17 mentions for Natera. Natera's average media sentiment score of 0.17 beat Exact Sciences' score of 0.12 indicating that Natera is being referred to more favorably in the media.
Exact Sciences received 495 more outperform votes than Natera when rated by MarketBeat users. Likewise, 72.40% of users gave Exact Sciences an outperform vote while only 68.48% of users gave Natera an outperform vote.
Natera presently has a consensus target price of $86.40, suggesting a potential downside of 9.68%. Exact Sciences has a consensus target price of $99.07, suggesting a potential upside of 66.55%. Given Exact Sciences' higher probable upside, analysts clearly believe Exact Sciences is more favorable than Natera.
99.9% of Natera shares are held by institutional investors. Comparatively, 88.8% of Exact Sciences shares are held by institutional investors. 7.6% of Natera shares are held by insiders. Comparatively, 1.3% of Exact Sciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Exact Sciences has a net margin of -8.17% compared to Natera's net margin of -40.16%. Exact Sciences' return on equity of -6.60% beat Natera's return on equity.
Natera has a beta of 1.38, indicating that its share price is 38% more volatile than the S&P 500. Comparatively, Exact Sciences has a beta of 1.26, indicating that its share price is 26% more volatile than the S&P 500.
Summary
Exact Sciences beats Natera on 10 of the 18 factors compared between the two stocks.
Get Natera News Delivered to You Automatically
Sign up to receive the latest news and ratings for NTRA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NTRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
